A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
17/03/2022at 09:36

Biogen lays out long-awaited Alzheimer’s data in obscure journal

On Wednesday, Biogen laid it all on the table for its embattled Alzheimer’s drug Aduhelm, publicizing results from two late-stage trials with the drug, but the company chose to do so in a lesser-known publication.
Photo: BRIAN SNYDER/REUTERS / X90051
By Angelica Peebles and Robert Langreth, bloomberg

Biogen Inc. on Wednesday published the full efficacy results from two late-stage studies of its Alzheimer’s disease drug Aduhelm in a lesser-known medical journal, nine months after US regulators cleared the treatment.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: BRIAN SNYDER/REUTERS / X90051

    Biogen and Eisai change agreements on Alzheimer's drug

    For subscribers

  • Photo: Pool New/Reuters/Ritzau Scanpix

    Biogen's Alzheimer's drug loses subsidies in the US

    For subscribers

  • Photo: BRIAN SNYDER/REUTERS / X90051

    Biogen slashes price of controversial Alzheimer's drug

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Foto: Viatris/PR.
Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

A market authorization application from US-based generics maker Viatris for a copy version of obesity treatment Wegovy breaches five of Novo Nordisk’s patents, claims the company in a lawsuit.
  • Novo Nordisk doubles obesity sales in 2022
  • New US lawsuit over insulin prices will have minimal impact on Novo Nordisk, says analyst

For subscribers

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Photo: Stine Tidsvilde
Pharma & biotech

Novo Nordisk meets upgraded guidance, setting new revenue record

For subscribers

Further reading

Foto: BRIAN SNYDER/REUTERS / X90051
Pharma & biotech

Biogen partner Eisai shares jump after FDA approves Alzheimer’s drug Leqembi

The Japanese company surged almost 10% in Tokyo trading following initial US clearance of Leqembi (lecanemab) for the treatment of Alzheimer’s disease.

For subscribers

Johan Luthman, executive vice president for research and development at Lundbeck | Foto: Lundbeck / Pr
Pharma & biotech

Lundbeck: Alzheimer's agitation drug can make a real difference

Head of R&D Johan Luthman is pleased that Lundbeck’s Alzheimer’s agitation treatment candidate has gotten the FDA’s priority designation – ”agitation is one of the most troublesome aspects of the disease.”

For subscribers

Foto: Mike Segar
Pharma & biotech

Lilly’s donanemab fails to get early FDA approval for Alzheimer’s

The FDA argues that not enough patients in a Lilly trial stayed on the company’s Alzheimer’s medicine for long enough to warrant accelerated approval.

For subscribers

Latest news

  • Novo Nordisk sues Viatris over copycat Wegovy – 12:46
  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Maersk and German start-up wants to enhance emission visibility for global e-trade – 08:27
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
  • Pfizer hopes Covid-19 sales will increase in the long run – 31 Jan
See all

Jobs

  • Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Senior Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Experienced Patent Counsel

  • Application Manager

  • Commercial Director

  • Application Manager

  • Lead Data Architect

See all jobs

Jobs

  • Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Senior Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Experienced Patent Counsel

  • Application Manager

  • Commercial Director

  • Application Manager

  • Lead Data Architect

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge